Marrone Bio Innovations to Present at LD Micro 500 Virtual Investor Conference
August 20 2020 - 8:31AM
Marrone Bio Innovations, Inc. (NASDAQ: MBII) (“Marrone Bio” or the
“Company”), an international leader in providing growers with
sustainable bioprotection and plant health solutions to support
global agricultural needs, today announced that management will
present at the LD 500 virtual investor conference, hosted by LD
Micro and taking place virtually September 1 – 4, 2020.
Jim Boyd, Chief Financial Officer of Marrone
Bio, is scheduled to host a virtual presentation during the
conference as follows and will participate in one-on-one meetings
with Chief Executive Officer Kevin Helash throughout the day.
LD 500 Virtual Investor
Conference
Date: Wednesday, September 2, 2020
Time: 1:20 p.m. Eastern time (10:20 a.m. Pacific time) – Track
1 Webcast:
https://www.webcaster4.com/Webcast/Page/2019/36186
A live audio webcast and archive of the
conference presentation will be available using the webcast link
above. For more information on the LD 500 virtual investor
conference or to schedule a one-on-one, please contact your LD
Micro representative.
About Marrone Bio
Innovations
Marrone Bio Innovations Inc. (NASDAQ: MBII) is a
growth-oriented company leading the movement to a more sustainable
world through the discovery, development and sale of innovative
biological products for crop protection, plant health and waterway
systems treatment that help customers operate more sustainably
while increasing their return on investment. MBI has screened over
18,000 microorganisms and 350 plant extracts, leveraging its
in-depth knowledge of plant and soil microbiomes enhanced by
advanced molecular technologies and natural product chemistry to
rapidly develop seven product lines. Supported by a robust
portfolio of over 400 issued and pending patents, MBI’s currently
available commercial products are Regalia®, Stargus®, Grandevo®,
Venerate®, Majestene®, Haven®, Pacesetter™, Zelto® Jet Oxide® and
Jet Ag® and Zequanox®, with a next-generation
insecticide-nematicide, a breakthrough bioherbicide and a
biofumigant in the Company’s product pipeline. MBI’s Pro Farm
Finland-based subsidiary employs a proprietary technology derived
from wood waste to stimulate plant growth and improve plant health,
resulting in improved yields and crop quality. Products include
UBP™ 110, Foramin®, UBP™ Seed Treatment, Foramin® ST.
Learn more about Marrone Bio Innovations at
www.marronebio.com. We also use our investor relations website,
https://investors.marronebio.com, as well as our corporate Twitter
account, @Marronebio, as means of disclosing material non-public
information, and encourage our investors and others to monitor and
review the information we make public in these locations. Follow us
on social media: Twitter, LinkedIn and Instagram.
Marrone Bio Innovations Forward Looking
Statements
This press release contains forward-looking
statements that involve substantial risks and uncertainties. All
statements, other than statements of historical facts, included in
this press release regarding strategy, future operations and plans,
including assumptions underlying such statements, are
forward-looking statements, and should not be relied upon as
representing MBI’s views as of any subsequent date. Examples
of such statements include statements regarding the timing of
Helash’s employment and appointment to the company’s board of
directors and the company’s goals for future performance. Such
forward-looking statements are based on information available to
the Company as of the date of this release and involve a number of
risks and uncertainties, some beyond the Company’s control, that
could cause actual results to differ materially from those
anticipated by these forward-looking statements, including the
recent uncertainty in the global economy and industry-specific
economy caused by the COVID-19 pandemic, consumer, regulatory and
other factors affecting demand for the Company’s products, weather,
regulatory and other factors affecting demand for the MBI’s
products, any difficulty in marketing MBI’s products in its target
markets, competition in the market for pest management products,
lack of understanding of bio-based pest management products by
customers and growers, and adverse decisions by regulatory agencies
and other relevant third parties. Additional information that could
lead to material changes in MBI’s performance is contained in its
filings with the SEC. MBI is under no obligation to, and expressly
disclaims any responsibility to, update or alter forward-looking
statements contained in this release, whether as a result of
current information, future events or otherwise.
Investor Relations Contact: Greg Falesnik or
Luke Zimmerman MZ Group – MZ North America Phone: 949-385-6449
MBII@mzgroup.us
Marrone Bio Innovations (NASDAQ:MBII)
Historical Stock Chart
From Mar 2024 to Apr 2024
Marrone Bio Innovations (NASDAQ:MBII)
Historical Stock Chart
From Apr 2023 to Apr 2024